Vascular Endothelial Growth Factors

A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.

Also Known As:

Networked: 619 relevant articles (22 outcomes, 72 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Ylä-Herttuala, Seppo: 7 articles (01/2021 - 05/2006)
2.	Loffredo, Stefania: 5 articles (08/2021 - 05/2010)
3.	Alitalo, Kari: 5 articles (01/2020 - 09/2002)
4.	Varricchi, Gilda: 4 articles (08/2021 - 01/2018)
5.	Marone, Gianni: 4 articles (06/2020 - 11/2006)
6.	Miyata, Yasuyoshi: 4 articles (01/2017 - 02/2006)
7.	Bremnes, Roy M: 4 articles (11/2015 - 02/2009)
8.	Busund, Lill-Tove: 4 articles (11/2015 - 02/2009)
9.	Cristinziano, Leonardo: 3 articles (08/2021 - 01/2018)
10.	Ferrara, Anne Lise: 3 articles (08/2021 - 06/2020)

Related Diseases

1.	Macular Edema 10/01/2023 - "Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA." 03/28/2023 - "A 33-year-old man previously treated with anti-VEGFs for macular edema came to our clinic for bilateral visual loss. " 11/01/2022 - "To investigate the impact of baseline vitreomacular interface status on treatment outcomes in patients treated with three different anti-vascular endothelial growth factors for diabetic macular edema. " 01/01/2022 - "Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review." 01/01/2022 - "Assessment of Anti-VEGFs in Treating Diabetic Macular Edema in Alfaisal Eye Center, Khartoum, Sudan, 2019."
2.	Retinal Vein Occlusion 01/01/2019 - "The current body of evidence on the efficacy and safety of anti-VEGFs for macular oedema secondary to branch retinal vein occlusion (BRVO) is steadily growing as large clinical trials and observational studies are continually completed. " 01/01/2017 - "A retrospective study was conducted at a single academic institution to identify 177 treatment naïve patients with macular oedema secondary to branch retinal vein occlusion (BRVO), hemiretinal vein occlusion (HRVO) and central retinal vein occlusion (CRVO) treated with intravitreal anti-VEGFs. " 09/01/2022 - "It is very important to recognize combined central retinal vein occlusion and cilioretinal artery occlusion as they could be treated with intravitreal injections of anti-vascular endothelial growth factors with favorable treatment outcomes." 01/01/2016 - "Comparison of anti-vascular endothelial growth factors, laser treatments and a combination of the both for treatment of central retinal vein occlusion." 06/14/2023 - "Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors - a population-based cohort study."
3.	Macular Degeneration (Age-Related Maculopathy) 01/01/2021 - "Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity outcomes: Results from the EAGLE study." 01/01/2020 - "Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration." 10/01/2023 - "In recent years, major progress has been made in treating the wet form of age-related macular degeneration (AMD) with anti-vascular endothelial growth factors, which reportedly stabilize and improve vision. " 05/22/2023 - "The patient was previously diagnosed with age-related macular degeneration and treated with anti-VEGFs. " 01/01/2023 - "Neovascular (wet) age-related macular degeneration (nAMD) is driven by VEGFs A, C, and D, which promote angiogenesis and vascular permeability. "
4.	Inflammation (Inflammations) 01/01/2010 - "Recent data suggest that basophils may also play a role in inflammation-related angiogenesis, principally but not exclusively through the expression of several forms of vascular endothelial growth factors and their receptors. " 01/01/2018 - "Although tumor cells produce VEGFs and other proangiogenic mediators, tissue resident (e.g., macrophages, mast cells) and circulating immune cells (e.g., basophils, neutrophils, monocytes, eosinophils) are an important source of angiogenic/lymphangiogenic mediators in inflammation and in tumor microenvironment and at site of chronic inflammation. " 04/01/2008 - "The immunohistochemical analysis of vascular endothelial growth factors A and C and microvessel density in gingival tissues of systemic sclerosis patients: their possible effects on gingival inflammation." 01/01/2018 - "The treatment should be aimed at reduction of the oxidative stress, and injection of inhibitors of vascular endothelial growth factors, glucocorticoids, etc. The study of para-inflammation and inflammation in AMD will help create a new generation of effective drugs that affect the key links in these processes. " 04/01/2014 - "Treatment of patients with corticosteroids induces regression of the inflammation in the posterior pole with downregulation of many cytokines including vascular endothelial growth factors. "
5.	Cataract (Cataracts) 02/25/2022 - "(3) Results: Intravitreal injection of anti-VEGFs provided short-term structural protection for one month in patients receiving cataract surgery, but the protective effect ceased to exist after three months. " 10/13/2023 - "The other parameters considered were the indications to the DME treatment, when to switch to DEX, the definition of non-responder to anti-VEGFs agents and to the DEX implant, whether to combine DEX with laser photocoagulation, the association between glaucoma and DEX, and the management of DEX and the cataract. " 10/01/2018 - "Intravitreal anti-VEGFs and steroids, in association with cataract surgery, are indicated for patients with preexisting diabetic macular edema or those at high risk of macular edema after surgery." 07/23/2014 - "The antivascular endothelial growth factors (VEGFs) are likely to be favoured because they are not associated with steroid-induced cataract formation. " 02/25/2022 - "The purpose of study is to compare the efficacy of topical nonsteroidal anti-inflammatory agents (NSAIDs) and intravitreal injections of anti-VEGFs for the prevention of macular edema after cataract surgery in diabetic patients without pre-existing macular edema. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Vascular Endothelial Growth Factors
3.	Ranibizumab (Lucentis)
4.	aflibercept
5.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
6.	Adrenal Cortex Hormones (Corticosteroids)
7.	Bevacizumab (Avastin)
8.	Retinaldehyde (Retinal)
9.	Dexamethasone (Maxidex)
10.	Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravitreal Injections
3.	Lasers (Laser)
4.	Vitrectomy
5.	Complementary Therapies (Alternative Medicine)